Fundz

Fundz Deep Dive

Everything you need to win Lutz Hilbrich — in one platform.

Who to reach, what to say, and why now on Lutz Hilbrich — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.

Get the full Deep Dive on Lutz Hilbrich — free.

One free Deep Dive, emailed to you. No spam; unsubscribe anytime.

Ready now? Choose your plan · Request a demo · Sign in

Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.

Halix B.V. Appoints Dr. Lutz Hilbrich As Chief Executive Officer (CEO) and Thanks Alex Huybens for Leadership

PRIVATESep 19, 2024•over 1 year ago

Position

Chief Executive Officer

Company

HALIX B.V

Lutz Hilbrich
LeidenManufacturingBiotechnology

Description

HALIX BV is pleased to announce the appointment of Dr Lutz Hilbrich as its new Chief Executive Officer (CEO), effective immediately. Dr Hilbrich brings over 20 years of experience in the biotechnology and pharmaceutical sectors, with a proven track record in the field of biosimilars, cell & gene therapy, and vaccines.

Company Information

Company

HALIX B.V

Location

Leiden, South Holland, Netherlands

About

HALIX B.V. is a biopharmaceutical CDMO for biologics, enabling the treatment and prevention of life-threatening diseases. The company is focused on mammalian expression systems for the production of viral vectors and recombinant proteins. HALIX leverages scalable single-use, state-of-the-art bioprocessing technologies to provide its customers with services for the development and GMP manufacturing of drug substances and drug products. HALIX has entered into a number of contracts for the production of oncolytic immunotherapies and vaccines, utilizing innovative technologies, most notably the large-scale commercial drug substance manufacture of AstraZeneca's COVID-19 vaccine. The company opened its state-of-the-art 6,700 m2 GMP manufacturing facility in 2019, offering 1,000 L SUB capacities, at the Leiden Bio Science Park, the Netherlands. HALIX is part of the family-owned Droege Group.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for HALIX B.V's next move

Learn about Strategic plan

Executive Insights

Based on hiring data
New executive impact window
87% of new executives make significant technology decisions within first 100 days
Budget influence
C-level executives control 73% of technology spending decisions
Transformation catalyst
65% of new senior hires launch digital transformation initiatives
Vendor review timeline
New executives typically review existing vendors within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.